Dan,

Talk to the Aventis lawyer directly.  Since it is your study, I would offer them the following:

The parties agree that Aventis shall be granted a non-exclusive option, exercisable within sixty (60) days following written notice of an INVENTION, to obtain an exclusive, worldwide, royalty-bearing license to all rights, title and interest which the INSTITUTION may have or obtain in any INVENTION.

Good Luck

scott

Scott Davis
Sponsored Programs Administrator
University of Oklahoma Health Sciences Center

Tel  405.271.2090
Fax 405.271.8651
xxxxxx@ouhsc.edu

-----Original Message-----
From: Daniel Christmus [mailto:xxxxxx@GWM.SC.EDU]
Sent: Thursday, January 23, 2003 1:57 PM
To: xxxxxx@HRINET.ORG
Subject: [RESADM-L] IP Issue-Pharmaceutical Company

Dear Colleagues,

I am currently in the process of negotiating a contract with Aventis
Pharmaceuticals, Inc.  This is a pre-clinical, investigator initiated
study.  The problem, as usual, deals with the IP language.  If you have
worked with Aventis recently, your insights would be appreciated.

Thanks,
Dan Christmus

Daniel L. Christmus
Sponsored Program Administrator
(803) 777-7093
(803) 777-4136 - fax

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================